Real World Study of Omeprazole–Domperidone in Acid Peptic Disease with Type 2 Diabetes (PRIDE 2)

Select Content Type
Resources
Authored By
Shalina MedSpace
Authored On
Interests
Cardiology
Dermatology
Emergency Medicine
Endocrinology
ENT
Gastroenterology
Hematology
Immunology Allergy & Inflammation
Infectious Disease & Vaccines
Internal/Family Medicine
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopedic
Pain & Anesthesiology
Pediatric Medicine
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology & Nephrology
Speciality
Cardiology
Dentistry
Dermatology
Emergency Medicine
Endocrinology
ENT
Gastroenterology
Geriatrics
Hematology
Immunology Allergy & Inflammation
Infectious Disease & Vaccines
Internal/Family Medicine
Medical Genetics
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopedic
Pain & Anesthesiology
Pathology
Pediatric Medicine
Pharmacology
Psychiatry
Public Health
Pulmonology
Radiology
Rheumatology
Surgery
Urology & Nephrology
Thumbnail Image
Real world_thumbnail
Detail Image
Real World_mobile
Book Detail
Actions
Download in App
Countries of release
India
Nigeria
UAE
IS_Ebsco
false
Description

The PRIDE-2 study retrospectively evaluated the effectiveness and safety of an omeprazole–domperidone combination for managing acid peptic disease (APD) in patients with type 2 diabetes mellitus across multiple Indian healthcare settings (2018–2021).

Among 174 patients, significant improvement in symptoms was observed over 120 days & no serious adverse events were reported. The omeprazole–domperidone combination was effective and well tolerated, offering substantial symptomatic relief in diabetic patients with APD.

Published Date